Holen Sie sich die Stockscreener-App
0.8839
5.18%
-0.0483
Vorhandelsmarkt:
.92
0.0361
+4.08%
Schlusskurs vom Vortag:
$0.9322
Offen:
$0.93
24-Stunden-Volumen:
695.49K
Relative Volume:
0.68
Marktkapitalisierung:
$88.22M
Einnahmen:
$1.63M
Nettoeinkommen (Verlust:
$-40.95M
KGV:
-1.506
EPS:
-0.5869
Netto-Cashflow:
$-18.80M
1W Leistung:
+1.83%
1M Leistung:
+5.25%
6M Leistung:
-64.64%
1J Leistung:
-18.16%
1-Tages-Spanne:
$0.882
$0.9385
1-Wochen-Bereich:
$0.8302
$0.9626
52-Wochen-Spanne:
$0.387
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Firmenname
Rani Therapeutics Holdings Inc
Sektor
Branche
Telefon
(408) 457-3700
Adresse
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.8839 | 88.22M | 1.63M | -40.95M | -18.80M | -0.5869 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Lake Street | Buy |
| 2024-08-02 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-14 | Eingeleitet | Maxim Group | Buy |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-07-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Rani Therapeutics Holdings Inc Aktie (RANI) Neueste Nachrichten
MSN Money - MSN
RANI Price Today: Rani Therapeutics Holdings, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Rani Therapeutics | SCHEDULE 13G: Others - Moomoo
Vanguard Capital Management takes 5.12% stake in Rani Therapeutics (RANI) - Stock Titan
Rani Therapeutics Holdings (RANI) price target decreased by 12.50% to 7.14 - MSN
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Rani Therapeutics Holdings (RANI) price target decreased by 13.51% to 8.16 - MSN
Form DEF 14AOther definitive proxy statements - ADVFN
Alireza Javadi Net Worth (2026) - GuruFocus
Rani Therapeutics | ARS: Annual Report to Security Holders - Moomoo
Rani Therapeutics (NASDAQ: RANI) sets 2026 virtual meeting on board elections and auditor - Stock Titan
[ARS] Rani Therapeutics Holdings, Inc. SEC Filing - Stock Titan
Rani Therapeutics (NASDAQ:RANI) Earns Buy Rating from Analysts at Lake Street Capital - MarketBeat
Rani Therapeutics appoints Sara Kenkare-Mitra as advisor By Investing.com - Investing.com Nigeria
Rani Therapeutics appoints Sara Kenkare-Mitra as advisor - Investing.com
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy - The Manila Times
Drug approval veteran joins Rani to shape oral biologics push - Stock Titan
Update Report: Can Rani Therapeutics Holdings Inc reach all time highs this yearPortfolio Update Report & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Is Rani (RANI) Stock a Good Buy in 2026 | Price at $0.82, Up 0.86%Collaborative Trading Signals - Cổng thông tin điện tử Tỉnh Sơn La
Published on: 2026-04-07 19:26:18 - baoquankhu1.vn
Is Rani (RANI) Stock Stronger Than Peers | Price at $0.88, Up 4.41%Elite Alerts - Cổng thông tin điện tử tỉnh Tây Ninh
RANI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Canaccord Genuity Group Lowers Rani Therapeutics (NASDAQ:RANI) Price Target to $5.00 - MarketBeat
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Market Review: Can Rani Therapeutics Holdings Inc reach all time highs this yearSwing Trade & Safe Entry Zone Tips - baoquankhu1.vn
Can Rani Therapeutics Holdings Inc beat the S P 5002026 Weekly Recap & Community Consensus Trade Alerts - baoquankhu1.vn
Loss Report: Is Rani Therapeutics Holdings Inc likely to announce a buybackMarket Risk Summary & High Conviction Buy Zone Picks - baoquankhu1.vn
RANI SEC FilingsRani Therapeutics Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Equities Analysts Offer Predictions for RANI Q1 Earnings - MarketBeat
Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In Growth - Yahoo Finance
Rani Therapeutics | 3: Initial statement of beneficial ownership of securities- Javadi Alireza - Moomoo
Rani Therapeutics (RANI) CTO discloses initial stock, RSU and option holdings - stocktitan.net
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Vanguard disaggregates holdings; reports 0 RANI shares (RANI) - Stock Titan
Rani Therapeutics (NASDAQ:RANI) Given "Buy" Rating at HC Wainwright - MarketBeat
Rani Therapeutics 2025 Annual Report: Oral Biologics Pipeline, Clinical Updates, and Risk Factors 535657 - Minichart
Earnings Call Summary | Rani Therapeutics(RANI.US) Q4 2025 Earnings Conference - news.futunn.com
Earnings call transcript: Rani Therapeutics Q4 2025 sees improved liquidity but misses EPS forecast - Investing.com Australia
Earnings call transcript: Rani Therapeutics Q4 2025 sees improved liquidity but misses EPS forecast By Investing.com - Investing.com South Africa
Rani Therapeutics Q4 Earnings Call Highlights - MarketBeat
Rani Therapeutics Holdings Inc reports results for the quarter ended September 30Earnings Summary - TradingView
RANI: Major Chugai deal, RT-114 clinical progress, and strengthened finances mark a transformative 2025 - TradingView
RANI: Advanced pipeline, secured major Chugai deal, and extended cash runway into Q4 2027 - TradingView
Rani Therapeutics 2025 10-K: $1.63M revenue, $(0.45) EPS - TradingView
RANI: Net loss improved to $41.0M in 2025, with $49.7M cash and strengthened by a $60.3M private placement - TradingView
Rani Therapeutics (NASDAQ: RANI) boosts cash, advances oral biologics pipeline - Stock Titan
Rani Therapeutics (NASDAQ:RANI) Announces Quarterly Earnings Results - MarketBeat
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update - The Manila Times
[8-K] Rani Therapeutics Holdings, Inc. Reports Material Event - Stock Titan
Finanzdaten der Rani Therapeutics Holdings Inc-Aktie (RANI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):